Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

OBJECTIVE: Avoiding abacavir in HIV-infected patients tested positive for HLA-B*5701 reduces the risk of abacavir hypersensitivity reaction (ABC-HSR). Our aim was to assess the costs of clinically suspected HSR and to estimate potential cost savings of implementing prospective HLA-B*5701-screening f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, E, Blankenburg, M, Bogner, JR, Becker, W, Gorriahn, D, Mueller, MC, Jaeger, H, Welte, R, Baudewig, M, Walli, R, Stoll, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400999/
https://www.ncbi.nlm.nih.gov/pubmed/20554495
http://dx.doi.org/10.1186/2047-783X-15-4-145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400999/
https://www.ncbi.nlm.nih.gov/pubmed/20554495
http://dx.doi.org/10.1186/2047-783X-15-4-145

Ejemplares similares